Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678995 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL6507462 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL4532629 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31370327 | 0.84 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL21639100 | 0.83 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL21639103 | 0.83 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31694964 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29907962 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL30069011 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL3725839 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190071483-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017062334-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071483-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885MDM2 4436/4885 |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885MDM2 4436/4885 |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885MDM2 4436/4885 |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885MDM2 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.